What's Happening?
Merck and Gilead Sciences have announced the discontinuation of their Phase 3 KEYNOTE-D46/EVOKE-03 study. This study was investigating the combination of Gilead's Trodelvy and Merck's KEYTRUDA in patients with previously untreated metastatic non-small
cell lung cancer (mNSCLC) whose tumors express PD-L1. The decision to halt the study was based on recommendations from an external Data Monitoring Committee after a review of progression-free survival and interim overall survival data. Although there was a numerical improvement in progression-free survival, it did not reach statistical significance, and the probability of achieving significant overall survival was deemed unlikely. The safety profile of the drug combination was consistent with known data, and no new safety concerns were identified.
Why It's Important?
The discontinuation of this study highlights the challenges in developing effective treatments for metastatic non-small cell lung cancer, a condition with limited treatment options and low long-term survival rates. The decision underscores the importance of statistical significance in clinical trials, as even numerical improvements must meet rigorous standards to justify continued research and potential approval. This outcome may impact stakeholders, including patients seeking new treatment options, healthcare providers, and the pharmaceutical companies involved. The decision also reflects the ongoing need for innovative therapies in oncology, particularly for cancers with high mortality rates.
What's Next?
Regulatory authorities have been informed of the study's discontinuation, and Merck will advise study investigators to discuss treatment options with their patients. While this particular study has ended, both companies continue to explore other avenues for cancer treatment. The data from this study will be presented at a future medical meeting, potentially contributing to the broader scientific understanding of lung cancer therapies. Ongoing studies involving Trodelvy and KEYTRUDA in other contexts remain unaffected, and the companies express gratitude to participants and healthcare professionals involved in the trial.
